Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRB-002 in established atherosclerosis
ACTRN12625000273482Phase 2Recruiting
- Sponsor
- Bitterroot Bio
- Start
- May 2025
- Modality
- Adoptive Cell Transfer → Cell Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerosis comparing BRB-002 with Placebo (2 arms). Primary endpoint: Safety and tolerability of multiple-dose subcutaneous BRB-002 administration. Started May 2025; status: recruiting.
02
Drugs
BRB-002
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on ACTRN12625000273482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000273482.